UMB

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Retrieved on: 
Monday, October 16, 2023

ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).

Key Points: 
  • SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
  • “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
  • In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.

UMB Announces Conference Call to Discuss Third Quarter 2023 Results

Retrieved on: 
Wednesday, October 4, 2023

UMB Financial Corporation (Nasdaq: UMBF), a financial services company, will release earnings results for the third quarter 2023 after market hours on Tuesday, October 24, 2023.

Key Points: 
  • UMB Financial Corporation (Nasdaq: UMBF), a financial services company, will release earnings results for the third quarter 2023 after market hours on Tuesday, October 24, 2023.
  • The company plans to host an investor conference call to discuss these results on Wednesday, October 25, 2023, at 8:30 a.m. (CT) / 9:30 a.m. (ET).
  • Interested parties may access the call by dialing (toll-free) 833-470-1428 or (international) 404-975-4839 and requesting to join the UMB Financial call with access code 879142.
  • The live call may also be accessed by visiting investorrelations.umb.com or by using the following the link:

Veritex Announces New President and Chief Banking Officer for Veritex Community Bank

Retrieved on: 
Tuesday, September 5, 2023

DALLAS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- (www.vertexbank.com) Veritex Holdings, Inc. (Nasdaq: VBTX) (“the Company” or “Veritex”), the holding company for Veritex Community Bank (“the Bank”), is pleased to announce, following an extensive nationwide search by Chartwell Partners, the hiring of Dominic Karaba as President and Chief Banking Officer of Veritex Community Bank effective Sept. 18.

Key Points: 
  • DALLAS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- (www.vertexbank.com) Veritex Holdings, Inc. (Nasdaq: VBTX) (“the Company” or “Veritex”), the holding company for Veritex Community Bank (“the Bank”), is pleased to announce, following an extensive nationwide search by Chartwell Partners, the hiring of Dominic Karaba as President and Chief Banking Officer of Veritex Community Bank effective Sept. 18.
  • Karaba has more than 28 years of experience in the banking industry and most recently served as UMB Financial Corporation’s President of Commercial Banking.
  • He has a bachelor’s degree in business from the University of Puget Sound and a graduate degree in banking and bank leadership from the Pacific Coast Graduate School of Banking.
  • Karaba will report directly to C. Malcolm Holland, III, who will remain Chief Executive Officer and Chairman of the Board of Veritex Community Bank as well as President, CEO and Chairman of the Board of Veritex Holdings, Inc.
    “We’re excited to have Dominic join our Veritex Bank family!

Swiss Firms Seek Innovative Ways to Control Rising IT Costs

Retrieved on: 
Wednesday, August 16, 2023

As a result, despite a relatively low profit margin, the managed hosting business in Switzerland remains significant, the ISG report says.

Key Points: 
  • As a result, despite a relatively low profit margin, the managed hosting business in Switzerland remains significant, the ISG report says.
  • “Even so, they should still plan for renegotiations with their current clients.”
    Providers are taking two principal routes to achieving their automation goals.
  • According to the ISG report, many Swiss firms are turning to technologies from niche providers instead of opting for costly conversions.
  • In addition, CANCOM and TCS are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant each.

UMB Launches Second Turnkey Registered Funds Solutions Platform as More Funds Choose Shared Services

Retrieved on: 
Monday, August 7, 2023

UMB Fund Services, Inc. (UMBFS), a subsidiary of UMB Financial Corporation (NASDAQ: UMBF), announced today the launch of its second turnkey Registered Fund Solutions (RFS) platform service for starting and operating unlisted closed-end funds.

Key Points: 
  • UMB Fund Services, Inc. (UMBFS), a subsidiary of UMB Financial Corporation (NASDAQ: UMBF), announced today the launch of its second turnkey Registered Fund Solutions (RFS) platform service for starting and operating unlisted closed-end funds.
  • “As our first RFS platform continued to grow, we knew we’d need a second, parallel platform to support demand,” said Maureen Quill, executive vice president and executive director, registered funds.
  • UMB Fund Services is a national leader in registered and alternative investment fund administration , providing a broad array of award-winning services for mutual funds and alternative investments.
  • UMB Fund Services offers fund accounting, administration, tax, investor services, transfer agency, custody, distribution and more.

Swiss Solutions Have Extra Appeal in Country’s Cybersecurity Market

Retrieved on: 
Wednesday, August 2, 2023

The 2023 ISG Provider Lens™ Cybersecurity - Solutions and Services report for Switzerland finds that many Swiss firms appreciate the local presence of service providers, not only for their proximity, but also for support that is speedy and relatively uncomplicated.

Key Points: 
  • The 2023 ISG Provider Lens™ Cybersecurity - Solutions and Services report for Switzerland finds that many Swiss firms appreciate the local presence of service providers, not only for their proximity, but also for support that is speedy and relatively uncomplicated.
  • “Clients in Switzerland often prefer providers from Switzerland,” said Roger Albrecht, partner and co-leader, ISG Cybersecurity, based in DACH.
  • “For success in the Swiss cybersecurity market, ‘Swissness’ can be key.”
    Although quantifying threat risks and proving the ROI of cybersecurity measures hasn’t been easy, Swiss executives are steadily coming to the realization that cyberattacks can lead to massive, possibly existential, financial and image damage.
  • Because small and medium-sized enterprises (SMEs) typically have less mature IT systems than large enterprises, there has been stepped-up demand for cybersecurity solutions in this sector, the ISG report says.

UMB Appoints New Leadership to its Institutional Banking Division

Retrieved on: 
Tuesday, July 18, 2023

UMB Financial Corporation (Nasdaq: UMBF) has announced the appointment of Phil Mason to the role of president, Institutional Banking .

Key Points: 
  • UMB Financial Corporation (Nasdaq: UMBF) has announced the appointment of Phil Mason to the role of president, Institutional Banking .
  • As president, Institutional Banking, Mason oversees UMB’s activities across corporate trust and agency services, institutional custody, fund services, the capital markets division, investor banking services, and healthcare services.
  • “Phil is the ideal leader to continue our strong momentum in the institutional space,” said Jim Rine, president and chief executive officer of UMB Bank.
  • He’s held multiple leadership roles in commercial banking and institutional banking during the past 16 years.

UMB Announces Conference Call to Discuss Second Quarter 2023 Results

Retrieved on: 
Thursday, July 6, 2023

UMB Financial Corporation (Nasdaq: UMBF), a financial services company, will release earnings results for the second quarter 2023 after market hours on Tuesday, July 25, 2023.

Key Points: 
  • UMB Financial Corporation (Nasdaq: UMBF), a financial services company, will release earnings results for the second quarter 2023 after market hours on Tuesday, July 25, 2023.
  • The company plans to host an investor conference call to discuss these results on Wednesday, July 26, 2023, at 9:30 a.m. (CT) / 10:30 a.m. (ET).
  • Interested parties may access the call by dialing (toll-free) 833-470-1428 or (international) 404-975-4839 and requesting to join the UMB Financial call with access code 835446.
  • The live call may also be accessed by visiting investorrelations.umb.com or by using the following the link:

UMB announces the addition of former State Street executive to Investment Managers Series Trust board

Retrieved on: 
Thursday, June 22, 2023

UMB Fund Services announced today the addition of Jim Ross to the Investment Managers Series Trust (IMST) Board of Trustees.

Key Points: 
  • UMB Fund Services announced today the addition of Jim Ross to the Investment Managers Series Trust (IMST) Board of Trustees.
  • Ross joins the board with more than 30 years of experience managing and marketing ETFs, mutual funds, and managed accounts.
  • “Jim’s extensive background in the asset management industry makes him a natural fit to join UMB’s IMST board,” said Maureen Quill, UMB executive director, registered funds.
  • He holds numerous other board positions including SPDR Series Trust 40 Act Board and Select Sector SPDR Trust 40 Act Board, which manage over 140 SPDR ETFs combined.

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

Retrieved on: 
Tuesday, May 30, 2023

ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.

Key Points: 
  • Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue
    ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its entry into a research agreement expanding the study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons.
  • Eric Weisblum, Chief Executive Officer of Silo Pharma, stated, “The initial three-month pilot study of SPU-21 assessed the peptide in healthy human and RA synovial tissue.
  • The next step is to further investigate cyclic peptides in human tissue assays for optimization and binding affinity.”
    Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).